Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $5.37 USD
Change Today +0.12 / 2.29%
Volume 554.6K
OSUR On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

orasure technologies inc (OSUR) Key Developments

OraSure Technologies Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Third Quarter of 2015

OraSure Technologies Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported net revenues of USD 30,388,000 against USD 26,401,000 a year ago. Operating income was USD 2,721,000 against USD 2,497,000 a year ago. Income before income tax was USD 2,626,000 against USD 2,355,000 a year ago. Net income was USD 2,968,000 or USD 0.03 per basic and diluted share compared USD 2,529,000 or USD 0.04 per diluted share a year ago. For the six months period, the company reported net revenues of USD 57,476,000 against USD 49,938,000 a year ago. Operating income was USD 2,430,000 against operating loss of USD 3,121,000 a year ago. Income before income tax was USD 2,744,000 against loss before income tax of USD 3,145,000 a year ago. Net income was USD 2,081,000 or USD 0.04 per basic and diluted share compared net loss of USD 3,102,000 or USD 0.06 per basic and diluted share a year ago. Capital expenditures were USD 1,145,000 compared to USD 1,988,000 a year ago. Cash used in operating activities was USD 3,421,000 compared to USD 10,397,000 a year ago. For the third quarter of 2015, on consolidated basis, the company is projecting net revenues of approximately USD 29.5 to USD 30.0 million. Bottom line performance of approximately breakeven to a net loss of USD 0.01 per share, primarily due to significantly higher costs expected under HCV co-promotion agreement coupled with the lower consolidated revenues.

OraSure Technologies, Inc. to Report Q2, 2015 Results on Aug 05, 2015

OraSure Technologies, Inc. announced that they will report Q2, 2015 results at 4:00 PM, US Eastern Standard Time on Aug 05, 2015

OraSure Technologies, Inc., Q2 2015 Earnings Call, Aug 05, 2015

OraSure Technologies, Inc., Q2 2015 Earnings Call, Aug 05, 2015

OraSure Technologies, Inc. Presents at 35th Annual Canaccord Genuity Growth Conference, Aug-12-2015 02:00 PM

OraSure Technologies, Inc. Presents at 35th Annual Canaccord Genuity Growth Conference, Aug-12-2015 02:00 PM. Venue: InterContinental Boston, 510 Atlantic Avenue, Boston, MA 02210, United States. Speakers: Douglas A. Michels, Chief Executive Officer, President and Director.

OraSure Technologies, Inc. Wins $10.4 Million HHS Contract to Advance Rapid Ebola Test Clinical Development

OraSure Technologies, Inc. announced that it has been awarded a contract for up to $10.4 million in total funding from the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response's Biomedical Advanced Research and Development Authority (BARDA) related to the Company's OraQuick® Ebola Rapid Antigen Test. The three-year, multi-phased contract includes an initial commitment of $1.8 million and options for up to an additional $8.6 million to fund certain clinical and regulatory activities.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OSUR:US $5.37 USD +0.12

OSUR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
American Bio Medica Corp $0.13 USD -0.009
Chembio Diagnostics Inc $4.25 USD +0.25
MedMira Inc C$0.04 CAD 0.00
Nymox Pharmaceutical Corp $2.21 USD +0.03
Pernix Therapeutics Holdings Inc $4.70 USD +0.10
View Industry Companies
 

Industry Analysis

OSUR

Industry Average

Valuation OSUR Industry Range
Price/Earnings 100.0x
Price/Sales 2.7x
Price/Book 1.9x
Price/Cash Flow 533.1x
TEV/Sales 1.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ORASURE TECHNOLOGIES INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.